Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | HRH1 | P35367 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26757990 | 0.95 | ALDH1A1 (0.63) | ALDH1A1KDM4EMAPTTSHRMAPK1 | |
| SCHEMBL3954399 | 0.88 | THRB (0.58) | ALDH1A1KDM4EGPR119POLBCHRM2 | |
| SCHEMBL9221205 | 0.88 | ALDH1A1 (0.65) | ALDH1A1KDM4EMAPTTSHRMAPK1 | |
| SCHEMBL5714160 | 0.85 | ACKR3 (0.52) | ALDH1A1KDM4EGPR119POLBCHRM2 | |
| SCHEMBL20097550 | 0.85 | ALDH1A1 (0.73) | ALDH1A1KDM4EMAPTTSHRMAPK1 | |
| SCHEMBL17986173 | 0.85 | KDM4E (0.55) | ALDH1A1KDM4EMAPTTSHRMAPK1 | |
| SCHEMBL3956276 | 0.85 | GPR119 (0.54) | ALDH1A1KDM4EGPR119POLBCHRM2 | |
| SCHEMBL28078173 | 0.84 | KDM4E (0.50) | ALDH1A1KDM4EMAPTTSHRMAPK1 | |
| SCHEMBL30521135 | 0.82 | GPR119 (0.54) | ALDH1A1KDM4EGPR119POLBCHRM2 | |
| SCHEMBL28705806 | 0.82 | GPR119 (0.54) | ALDH1A1KDM4EGPR119POLBCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107001344-B | Piperazine derivatives for the treatment of disorders | 艾科耐特有限公司 | 2021-02-26 | — | — | CN | disclosed |
| EP-3131886-B1 | PIPERAZINE DERIVATIVES FOR TREATING DISORDERS | EXONATE LTD (GB) | 2020-09-09 | — | — | EP | disclosed |
| EP-3131886-B1 | PIPERAZINE DERIVATIVES FOR TREATING DISORDERS | EXONATE LTD (GB) | 2020-09-09 | — | — | EP | disclosed |
| US-9932330-B2 | Piperazine derivatives for treating disorders | THE UNIVERSITY OF NOTTINGHAM (GB) | 2018-04-03 | — | — | US | disclosed |
| US-9932330-B2 | Piperazine derivatives for treating disorders | THE UNIVERSITY OF NOTTINGHAM (GB) | 2018-04-03 | — | — | US | disclosed |
| US-9932330-B2 | Piperazine derivatives for treating disorders | THE UNIVERSITY OF NOTTINGHAM (GB) | 2018-04-03 | — | — | US | disclosed |
| US-20180044331-A1 | PIPERAZINE DERIVATIVES FOR TREATING DISORDERS | EXONATE LIMITED (GB) | 2018-02-15 | — | — | US | disclosed |
| US-20180044331-A1 | PIPERAZINE DERIVATIVES FOR TREATING DISORDERS | EXONATE LIMITED (GB) | 2018-02-15 | — | — | US | disclosed |
| US-20180044331-A1 | PIPERAZINE DERIVATIVES FOR TREATING DISORDERS | EXONATE LIMITED (GB) | 2018-02-15 | — | — | US | disclosed |
| US-9796707-B2 | Piperazine derivatives for treating disorders | THE UNIVERSITY OF NOTTINGHAM (GB) | 2017-10-24 | — | — | US | disclosed |
| EP-2445495-A1 | COMPOSITION FOR TREATMENT OF TUBERCULOSIS | Bioversys AG (CH) | 2012-05-02 | — | — | EP | disclosed |
| US-20120101080-A1 | COMPOSITION FOR TREATMENT OF TUBERCULOSIS | BioVersys AG (CH) | 2012-04-26 | — | — | US | disclosed |
| WO-2012019430-A1 | PHTHALAZINONE DERIVATIVE, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | 上海恒瑞医药有限公司 (CN) | 2012-02-16 | — | — | WO | disclosed |
| WO-2012012314-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-01-26 | — | — | WO | disclosed |
| WO-2010149761-A1 | COMPOSITION FOR TREATMENT OF TUBERCULOSIS | BIOVERSYS GMBH (CH) | 2010-12-29 | — | — | WO | disclosed |
| US-20100168123-A1 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2010-07-01 | — | — | US | disclosed |
| EP-1684694-A2 | AKT PROTEIN KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20050130954-A1 | Serine/threonine protein kinase inhibitors; hyperproliferative disorder or inflammatory conditions; e.g. 4-(4-(2-amino-3-(p-chlorophenyl)-propionyl)-piperazin-1-yl)-quinazoline | ARRAY BIOPHARMA INC. | 2005-06-16 | — | — | US | disclosed |
| WO-2005051304-A2 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2005-06-09 | — | — | WO | disclosed |
| EP-0528172-A1 | (2-Alkyl-3-pyridyl)methylpiperazine derivatives as PAF antagonists | J. URIACH & CIA. S.A. (ES) | 1993-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101080-A1 | COMPOSITION FOR TREATMENT OF TUBERCULOSIS | PRMT7, NCOA3, PRMT3 | ALDH1A1 3428/4885KDM4E 930/4885MAPT 2520/4885 |
| US-20100168123-A1 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | ALDH1A1 3849/4885KDM4E 2590/4885MAPT 3331/4885 |
| US-20180044331-A1 | PIPERAZINE DERIVATIVES FOR TREATING DISORDERS | PGF, GAP43, VHL | ALDH1A1 1203/4885KDM4E 2903/4885MAPT 222/4885 |
| US-20050130954-A1 | Serine/threonine protein kinase inhibitors; hyperproliferative disorder or inflammatory conditions; e.g. 4-(4-(2-amino-3-(p-chlorophenyl)-propionyl)-piperazin-1-yl)-quinazoline | MTOR, CDK2, CLK2 | ALDH1A1 3868/4885KDM4E 1872/4885MAPT 3207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.